What Researchers Did
Turkish doctors reported three newborn cases where HBOT was used as a last-resort treatment for life- or limb-threatening conditions including arterial blockage, blood clot with compartment syndrome, and a non-healing surgical wound.
What They Found
All three neonates received HBOT as an add-on to standard medical treatment. Outcomes included tissue salvage and improved wound healing in cases where standard treatment alone was insufficient. No serious HBOT-related adverse events were reported in any of the three infants.
What This Means for Canadian Patients
For Canadian neonatal intensive care units managing infants with severe vascular or wound complications, this small case series suggests HBOT may be a viable adjunct when standard options have failed. Safety in newborns at appropriate HBOT pressures appears acceptable based on this limited evidence.
Canadian Relevance
No direct Canadian connection identified. Neonatal HBOT is not a standard or OHIP-covered indication, but this report supports further investigation.
Study Limitations
Three cases are far too few to establish safety or efficacy; this report only demonstrates feasibility and calls for more structured research.